Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials

MLA

Djalali, S., et al. “Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials.” Djalali, S; Valeri, F; Gerber, B; Meli, D N; Senn, O (2017). Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clinical and Applied Thrombosis/Hemostasis, 23(6):685-695, 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.ocn959657152&authtype=sso&custid=ns315887.

APA

Djalali, S., Valeri, F., Gerber, B., Meli, D. N., & Senn, O. (2017). Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Djalali, S; Valeri, F; Gerber, B; Meli, D N; Senn, O (2017). Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clinical and Applied Thrombosis/Hemostasis, 23(6):685-695.

Chicago

Djalali, S, F Valeri, B Gerber, D N Meli, and O Senn. 2017. “Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials.” Djalali, S; Valeri, F; Gerber, B; Meli, D N; Senn, O (2017). Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clinical and Applied Thrombosis/Hemostasis, 23(6):685-695. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.ocn959657152&authtype=sso&custid=ns315887.